S. Dhe-Paganon

This study identifies a new IMiD-independent drug targeting SALL4's ZFC4 domain, leading to significant tumor growth inhibition in vivo.

This paper describes a high-throughput screening method using human PBMCs to identify adjuvant candidates, resulting in a lead compound with in vivo adjuvanticity.

This paper develops a covalent inhibitor of the YAP-TEAD complex, demonstrating its ability to suppress Hippo signaling defects and inhibit cancer cell growth.

This paper develops PRPK-directed phthalimides based on pomalidomide, identifies a potent and selective PRPK binder, and highlights distinct binding mechanisms compared to cereblon.

This study identifies an adjuvanted SARS-CoV-2 RBD nanoparticle that induces neutralizing antibodies and full protection in aged mice.

This study shows autophosphorylation of small GTPases like H-RAS and K-RAS alters their nucleotide exchange and effector interactions, changing their functional behavior.

This study evaluates AH:CpG adjuvant's ability to enhance RBD vaccine efficacy in aged mice and human elder cells, showing strong neutralizing antibody responses and cytokine production.

Sulfopin, a selective Pin1 inhibitor, reduces tumor initiation and growth in neuroblastoma models by targeting c-Myc pathways.

The paper identifies a mechanism by which RNA granules are transported via direct interaction with KIF5A/KLC1 motors, preventing axon degeneration in CMT models.

This study identifies THZ-P1-2, a covalent pan-PI5P4K inhibitor, showing efficacy in AML/ALL cell lines and autophagy disruption, supporting PI5P4Ks as therapeutic targets in cancer.

The paper identifies LOH of essential genes as a class of non-driver cancer vulnerabilities by showing allele-specific inactivation can selectively kill cancer cells.